Latest Somatic hypermutation Stories
Adds Immuno-Oncology Development Strength to AnaptysBio's Product Pipeline SAN DIEGO, April 6, 2015 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic
Novel methodology leverages somatic hypermutation to rapidly generate humanized therapeutic antibodies with >97% human content SAN DIEGO, April 3, 2014 /PRNewswire/ -- AnaptysBio,
SAN DIEGO, March 13, 2014 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration
Scientists at USC have created a mathematical model that explains and predicts the biological process that creates antibody diversity – the phenomenon that keeps us healthy by generating robust immune systems through hypermutation.